A phase 1 safety evaluation of oral enzastaurin in combination with bevacizumab in patients with advanced/metastatic cancer
Phase of Trial: Phase I
Latest Information Update: 18 May 2018
At a glance
- Drugs Bevacizumab; Enzastaurin
- Indications Cancer
- Focus Adverse reactions; Biomarker; Pharmacokinetics; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 07 Jun 2012 Planned end date changed from 1 Dec 2008 to 1 Mar 2013 as reported by ClinicalTrials.gov.
- 07 Jun 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.